- Home
- SGD vs XRTX Comparison
SGD vs XRTX Comparison
Compare SGD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- XRTX
- Stock Information
- Founded
- SGD 2021
- XRTX 2011
- Country
- SGD United States
- XRTX Canada
- Employees
- SGD N/A
- XRTX N/A
- Industry
- SGD
- XRTX Pharmaceuticals and Biotechnology
- Sector
- SGD
- XRTX Health Care
- Exchange
- SGD Nasdaq
- XRTX Nasdaq
- Market Cap
- SGD 5.0M
- XRTX 5.0M
- IPO Year
- SGD N/A
- XRTX N/A
- Fundamental
- Price
- SGD $3.19
- XRTX $1.82
- Analyst Decision
- SGD
- XRTX Strong Buy
- Analyst Count
- SGD 0
- XRTX 1
- Target Price
- SGD N/A
- XRTX $14.00
- AVG Volume (30 Days)
- SGD 973.1K
- XRTX 125.9K
- Earning Date
- SGD 01-01-0001
- XRTX 11-14-2024
- Dividend Yield
- SGD N/A
- XRTX N/A
- EPS Growth
- SGD N/A
- XRTX N/A
- EPS
- SGD N/A
- XRTX N/A
- Revenue
- SGD $91,978.00
- XRTX N/A
- Revenue This Year
- SGD N/A
- XRTX N/A
- Revenue Next Year
- SGD N/A
- XRTX N/A
- P/E Ratio
- SGD N/A
- XRTX N/A
- Revenue Growth
- SGD N/A
- XRTX N/A
- 52 Week Low
- SGD $2.66
- XRTX $1.09
- 52 Week High
- SGD $168.40
- XRTX $67.72
- Technical
- Relative Strength Index (RSI)
- SGD 34.16
- XRTX 53.06
- Support Level
- SGD $2.66
- XRTX $1.52
- Resistance Level
- SGD $6.61
- XRTX $2.51
- Average True Range (ATR)
- SGD 0.88
- XRTX 0.28
- MACD
- SGD -0.20
- XRTX 0.04
- Stochastic Oscillator
- SGD 12.50
- XRTX 31.00
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.